Page 3 - Sinovant Sciences News Today

Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) shares are trading higher by 48% at $2.19 Wednesday morning after the company, and Sinovant Sciences, announced topline results from the Phase 3 trial of lefamulin in Chinese adults with community-acquired bacterial pneumonia. Nabriva Therapeutics is a clinical-stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of ant...

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/ Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angions AKI-002-15 study, a phase-II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidne...

More from AP